within Pharmacolibrary.Drugs.ATC.H;

model H01CC04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.92,
    Cl             = 6.0666666666666666e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0526,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009333333333333334,
    Tlag           = 19.8,            
    Vdp             = 0.31,
    k12             = 29,
    k21             = 29
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H01CC04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Linzagolix is an oral, selective, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist used for the treatment of uterine fibroids and endometriosis in women of reproductive age. It reduces estrogen levels by suppressing the hypothalamic-pituitary-gonadal axis. Linzagolix is approved in the European Union but not in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy premenopausal women after oral administration.</p><h4>References</h4><ol><li><p>Barretta, M, et al., &amp; Grandi, G (2024). The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications. <i>Expert opinion on drug metabolism &amp; toxicology</i> None 1–13. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2024.2441981&quot;>10.1080/17425255.2024.2441981</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39666595/&quot;>https://pubmed.ncbi.nlm.nih.gov/39666595</a></p></li><li><p>Pohl, O, et al., &amp; Gotteland, JP (2022). A model-based analysis to guide gonadotropin-releasing hormone receptor antagonist use for management of endometriosis. <i>British journal of clinical pharmacology</i> 88(5) 2359–2371. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15171&quot;>10.1111/bcp.15171</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34904270/&quot;>https://pubmed.ncbi.nlm.nih.gov/34904270</a></p></li><li><p>Rovelli, RJ, et al., &amp; Hutcherson, TC (2022). Systematic review of oral pharmacotherapeutic options for the management of uterine fibroids. <i>Journal of the American Pharmacists Association : JAPhA</i> 62(3) 674–682.e5. DOI:<a href=&quot;https://doi.org/10.1016/j.japh.2022.02.004&quot;>10.1016/j.japh.2022.02.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35277362/&quot;>https://pubmed.ncbi.nlm.nih.gov/35277362</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H01CC04;
